New Astra-Zeneca B.1.351 vaccine AZD2816 strongly immunogenic against multiple SARS-CoV-2 variants o …

843005

Sumary of New Astra-Zeneca B.1.351 vaccine AZD2816 strongly immunogenic against multiple SARS-CoV-2 variants of concern:

  • Simultaneously, however, new strains are emerging that show resistance to antibodies elicited by earlier strains, and/or increased transmissibility..
  • All VOCs identified so far contain the D614G mutation that increases infectivity, possibly by increasing the expression of the spike protein on the surface of the viral particle..
  • The L452R mutation is present in B.1.429 (Epsilon), B.1.617.1 and B.1.617.2, reducing susceptibility to neutralizing antibodies..
  • E484K in both B.1.351 and P.1 isolates may increase spike-receptor binding as well as conferring antibody escape capability..
  • This variant contains N501Y and 484K, among other mutations in the spike protein, of which three are thought to enhance spike-receptor binding affinity..
  • The B.1.351 variant was first reported in October 2021, with three RBD mutations that increase spike-RBD binding and thus impaired neutralizing capacity..
  • Adenovirus-vectored and mRNA-based vaccines are easily tailored to incorporate mutated spike antigens to meet the challenges posed by newer variants..
  • Single-dose of AZD2816 produces cross-reactive immunity In the current experiment, the researchers found that a single dose of either the new vaccine or the original ChAdOx1 nCoV-19 (AZD1222) vaccine produced a robust antibody response….

Want to know more click here go to source.

From -
Close
Generic selectors
Exact matches only
Search in title
Search in content

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close